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Functional interactions between
transient receptor potential M8 and
transient receptor potential V1 in
the trigeminal system: Relevance
to migraine pathophysiology
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Abstract
Background: Recent genome-wide association studies have identified transient receptor potential M8 (TRPM8) as a
migraine susceptibility gene. TRPM8 is a nonselective cation channel that mediates cool perception. However, its precise
role in migraine pathophysiology is elusive. Transient receptor potential V1 (TRPV1) is a nonselective cation channel
activated by noxious heat. Both TRPM8 and TRPV1 are expressed in trigeminal ganglion (TG) neurons.
Methods:We investigated the functional roles of TRPM8 and TRPV1 in a meningeal inflammation-based migraine model
by measuring the effects of facial TRPM8 activation on thermal allodynia and assessing receptor coexpression changes in
TG neurons. We performed retrograde tracer labeling to identify TG neurons innervating the face and dura.
Results: We found that pharmacological TRPM8 activation reversed the meningeal inflammation-induced lowering of
the facial heat pain threshold, an effect abolished by genetic ablation of TRPM8. No significant changes in the heat pain
threshold were seen in sham-operated animals. Meningeal inflammation caused dynamic alterations in TRPM8/TRPV1
coexpression patterns in TG neurons, and colocalization was most pronounced when the ameliorating effect of TRPM8
activation on thermal allodynia was maximal. Our tracer assay disclosed the presence of dura-innervating TG neurons
sending collaterals to the face. Approximately half of them were TRPV1-positive. We also demonstrated functional
inhibition of TRPV1 by TRPM8 in a cell-based assay using c-Jun N-terminal kinase phosphorylation as a surrogate marker.
Conclusions: Our findings provide a plausible mechanism to explain how facial TRPM8 activation can relieve migraine
by suppressing TRPV1 activity. Facial TRPM8 appears to be a promising therapeutic target for migraine.
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Introduction
Migraine-related disabilities are frequently uncontrol-
lable, mainly because current migraine management
remains suboptimal. Traditionally, cooling of craniofa-
cial structures has been used to relieve migraine head-
aches. The perception of cool temperatures (<23C) is
mediated by transient receptor potential M8 (TRPM8),
a nonselective cation channel activated by cooling
agents such as menthol and icilin (1–4). TRPM8 is
abundantly expressed in trigeminal ganglion (TG)
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neurons (1,2). Intriguingly, a randomized placebo-
controlled study demonstrated that menthol applica-
tion to the face was eﬀective in aborting migraine
attacks (5), suggesting TRPM8 activation as a possible
therapeutic strategy for migraine.
A widely-accepted mechanism posits that migraine
headache is caused by activation of the trigeminovas-
cular system, including TG neurons innervating the
dura mater, where calcitonin gene-related peptide
(CGRP) acts as an important neurotransmitter (6,7).
The tenet that the disease locus responsible for migraine
headache lies in the peripheral nervous system is con-
sistent with the recently reported eﬃcacy of monoclonal
antibodies against CGRP or its receptor in migraine
prophylaxis (8–11). Moreover, several genome-wide
association studies (GWASs) have identiﬁed TRPM8
as a candidate susceptibility gene for migraine (12–14).
Nevertheless, the precise pathogenic role of TRPM8
remains unknown, although as stated above, TRPM8
activation is likely protective against migraine (5).
Another member of the TRP family, transient recep-
tor potential V1 (TRPV1), is a nonselective cation
channel that is activated by noxious stimuli such as
high temperatures (>43C) and capsaicin stimulation
(15). TRPV1 colocalizes with CGRP in nociceptive
TG neurons. The cation channel is also implicated in
migraine pathophysiology. When activated, TRPV1
promotes CGRP release from trigeminal terminals
(16). Moreover, a recent study reported increased
TRPV1 expression in the trigeminal ﬁbers of chronic
migraine patients (17).
The meningeal inﬂammation induced by inﬂamma-
tory soup (IS) is known to cause a transient sensitiza-
tion of the dural trigeminal system (18) and is used as a
migraine model in rodents (19–21). We found that
IS-induced meningeal inﬂammation lowered the thresh-
old temperature for heat pain withdrawal of the face.
Pharmacological activation of TRPM8 with icilin
reversed this thermally sensitized state, an action that
was abrogated by genetic deletion of TRPM8. In par-
allel, IS-induced meningeal inﬂammation caused
dynamic changes in the expression of TRPM8 and
TRPV1 in TG neurons, accompanied by increased
channel colocalization. Our retrograde tracer assay
identiﬁed TG neurons innervating both the dura and
the face. Although these neurons were found in the
ophthalmic (V1) and maxillary (V2) divisions of the
TG, the former segment was found to harbor a signiﬁ-
cantly larger number of such neurons. We also demon-
strated cell-autonomous functional inhibition of
TRPV1 by TRPM8 in a cell culture system. These ﬁnd-
ings provide invaluable insights into the role of TRPM8
in migraine pathophysiology and could lead to the
development of novel TRPM8-based therapeutic
strategies.
Materials and methods
Animals
Male C57BL/6 mice (CLEA Japan Inc., N¼ 66, age
1012 weeks, 2025 g) and TRPM8 knockout (KO)
mice (Jackson Laboratory, Bar Harbor, ME, N¼ 24,
age 12–16 weeks, 2227 g) were used in this study.
They were housed in cages with free access to water
and food. Three animals were used for a dual retro-
grade tracer assay, nine animals for in situ hybridiza-
tion, 30 animals for immunohistochemistry, and the
remaining animals for behavioral analysis of facial
heat pain. All experimental procedures were approved
by the Laboratory Animal Care and Use Committee of
Keio University (Authorization No. 14005), and all
studies were conducted in accordance with the
ARRIVE (Animal Research: Reporting of In Vivo
Experiments) guidelines.
IS-induced meningeal inflammation model
Mice were anesthetized with isoﬂurane (1.0% in room
air) at 37C. We installed a small open cranial window
2mm in diameter centered at bregma. After the dura
mater was exposed, inﬂammation was induced by
locally applying 5 ml of IS (1mM each of histamine,
serotonin, and bradykinin and 0.1mM prostaglandin
E2 in 10mM HEPES buﬀer, pH 5.5) (20). The appli-
cation site was then covered with the skull bone and
dental cement. As we used the small amount of IS, and
the overlying skull bone was already denervated, con-
cern for spread of IS to the surrounding tissue and
stimulation of periosteal trigeminal endings was min-
imal. The mice were sacriﬁced six hours, 24 hours
(Day 1), 48 hours (Day 2), or six days (Day 6) after
inﬂammation induction. Sham-operated mice under-
went the same craniotomy but no IS treatment, and
were sacriﬁced six days later. Control animals did not
undergo any surgical procedure or IS treatment.
Behavioral heat pain test
Before surgery (described above), mice were pretrained
until they were consistently able to stay calm in an
experimental apparatus that restricted body mobility
except for head movement. On the day before experi-
mental data collection, successfully pretrained mice
were anesthetized with 1% isoﬂurane, and facial hair
was removed. The next day, a pair of Peltier module
bars with surface temperature regulated between 36C
and 56C was applied to the face bilaterally. The bars
were in contact with the bilateral periorbital regions
and whiskers. The bar surface temperature was grad-
ually elevated from 36C by 1C/4 seconds until face
withdrawal, a behavior index of thermal nociception.
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Mouse behaviors were monitored by a video recorder
(Panasonic, Kadoma Japan). Video analysis was per-
formed by an examiner blind to the identity of the ani-
mals. The lowest temperature at which a mouse averted
the head away from the bars was considered the heat
pain threshold temperature for the animal. In each ses-
sion, measurement of the threshold temperature was
repeated ﬁve times. After baseline thresholds were col-
lected, the mice were subjected to sham operation or
IS-induced meningeal inﬂammation as described.
A 5mm 5mm piece of ﬁlter paper immersed in
either icilin (10mM) or vehicle (dimethyl sulfoxide:
DMSO) was applied to the face on each side for ﬁve
min. This treatment was carried out 30min prior to
each behavioral test. We remeasured threshold tem-
peratures at six hours, 24 hours (Day 1), 48 hours
(Day 2), and six days (Day 6) after IS administration.
As for the sample size calculation for the behavioral
study, our preliminary experiments revealed that the
standard deviation (SD) of the heat pain threshold tem-
perature of untreated control mice was 0.5C. With the
type I error rate and power being 5% and 0.80, respect-
ively, if we were to detect a 0.5–1.0C diﬀerence, the
sample size required was calculated as 4–16.
Accordingly, we used six animals and measured the
threshold temperature in pentaplicate at every measur-
ing time point, as stated above.
Immunostaining and in situ hybridization
TG tissue was prepared as described elsewhere (22,23).
Serial sections of 10 mm thickness were prepared for
histological examination. Sections were immunostained
with rabbit anti-TRPM8 (KM060, TransGenic Inc.,
Kobe, Japan) and goat anti-TRPV1 (sc-12498, Santa
Cruz Biotechnology, Dallas, TX). Immunoreactivity
was visualized using species-speciﬁc donkey secondary
antibodies conjugated to Cy3 or ﬂuorescein isothio-
cyanate (FITC) (Jackson ImmunoResearch Labs,
West Grove, PA). We also immunostained tissue sec-
tions obtained from TRPM8 KO mice with the
TRPM8 antibody to check its speciﬁcity. Nuclei were
counterstained with 4’,6-diamidino-2-phenylindole
(DAPI: Sigma-Aldrich, St. Louis, MO). The immuno-
labeled specimens were examined under a Keyence
BIOREVO BZ-9000 microscope (Keyence, Osaka,
Japan) and a TCS-SP5 confocal laser scanning micro-
scope (Leica Microsystems, Mannheim, Germany). For
cell counting, we counted TRPM8-positive and
TRPV1-positive cells and calculated the ratio of each
to all DAPI-positive neurons. We also calculated the
proportion of TRPM8-positive cells in the entire
TRPV1-positive cell population. We conducted in situ
hybridization for TRPM8 mRNA according to a
protocol described elsewhere (23). The probe sequences
were designed for nucleotides 279978 of the mouse
TRPM8 cDNA sequence (GenBank Accession No.:
AF481480).
Identification of TG neurons innervating
the dura and face by retrograde tracers
To conﬁrm the existence of TG neurons innervating
both the dura and face, under anesthesia with 1–2%
isoﬂurane, the retrograde axonal tracers Fluorogold
(FG; Biotium, Hayward, CA) and DiI (Life
Technologies, Carlsbad, CA) were applied to the dura
and subcutaneous tissue of both whisker pads of
untreated wild-type mice, respectively. For FG admin-
istration, a round piece (2mm in diameter) of the skull
bone at bregma was removed. Care was taken not to
damage the underlying dura. FG (approximately
100 mg) was put evenly over the surface of the exposed
dura. The skull bone piece was returned, and the
overlying skin was sutured. Meanwhile, DiI solution
(20mg/ml, 50 ml) was injected into the subcutaneous
tissue of the bilateral periorbital regions and whisker
pads. After recovery from anesthesia, the animals were
kept individually with free access to food and water.
Three days after tracer application, the animals
(N¼ 3) were sacriﬁced and transcardially perfused
with 4% paraformaldehyde/phosphate-buﬀered saline.
The bilateral TGs were dissected out, and 10 mm thick
TG tissue sections were prepared on a cryostat. For
tissue sections containing the V1 and V2 divisions of
the TG, the numbers of tracer-labeled cells were
counted by three independent examiners. We per-
formed TRPV1 immunostaining for a subset of sections
prepared from these TG samples in the same protocol
described above.
Stable transformants expressing an emerald
GFP (EmGFP)-rat full-length TRPM8-V5 epitope
fusion protein
Total RNA was prepared from the TG of an adult male
Sprague-Dawley rat using TRIZOL LS Reagent (Life
Technologies). cDNA was synthesized using the
SuperScript III First-Strand Synthesis System (Life
Technologies). Full-length TRPM8 cDNA was ampli-
ﬁed by PCR using a set of sequence-speciﬁc primers
(forward: 5’-caccatggccttcgagggagccagg-3’, reverse:
5’-tttgactttattagcaatctctttcag-3’). The ampliﬁed DNA
fragment was subcloned into pcDNATM3.2-DEST
(Life Technologies). The EmGFP-rat full-length
TRPM8-V5 expression vector was transfected into
PC12 cells using Lipofectamine 2000 (Life
Technologies). Clones of stably transfected cells were
isolated using 10 mg/ml Blasticidin (Life Technologies).
All experimental procedures were approved by Keio
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University School of Medicine Safety Committee on
Genetically Modiﬁed Organisms (Authorization No.
20-017-5).
Calcium imaging
EmGFP-rat full-length TRPM8-V5-expressing PC12
cells were incubated with 5 mM Rhod-2 AM (Thermo
Fisher Scientiﬁc, Waltham, MA) in imaging solution
containing 117mM NaCl, 2.5mM KCl, 2mM CaCl2,
2mM MgSO4, 25mM HEPES, and 30mM D-(þ)-glu-
cose, (pH 7.4) at 37C for 20min, followed by washing
for 30min in the imaging solution. For image capture,
the cells were perfused at 10ml/min with the imaging
solution at room temperature and then exposed to the
imaging solution, containing varying concentrations of
icilin. Images were acquired at 2Hz (500ms exposure
time) with a cooled CCD camera (Andor iXon,
DU897) connected to a Nikon Eclipse microscope
with a 20 (NA 0.45) objective lens. Imaging analysis
was performed with ImageJ software (NIH).
Western blot analysis
Western blotting of cell lysates was conducted as
described (22). Blotting membranes were serially incu-
bated with primary antibodies and species-speciﬁc
horseradish peroxidase (HRP)-conjugated secondary
antibodies (Jackson ImmunoResearch Labs).
Immunoreactivity was visualized using Western
Lightning Plus-ECL, Enhanced Chemiluminescence
Substrate (Perkin Elmer, Waltham, MA). The primary
antibodies used were as follows: Anti-V5 (46-0705, Life
Technologies), anti-phospho-c-Jun N-terminal kinase
(JNK) (4668, Cell Signaling Technology, Danvers,
MA), and anti-total JNK (9252, Cell Signaling
Technology). Densitometric analysis of immunoreac-
tive bands was conducted using Multigauge software
v. 3.3 (Fuji Film, Tokyo, Japan).
Statistical analysis
All quantitative data on pain threshold temperature
and band intensities are expressed as the mean SD.
Levene’s test was used to assess the equality of vari-
ances for numerical data across groups. In the behav-
ioral test, group means were ﬁrst compared by two-way
analysis of variance (ANOVA) to check whether there
was any signiﬁcant interaction between independent
variables, followed by multiple comparison with
Bonferroni’s post hoc test. For cell counting, we used
a chi-square test for comparison. For analysis of west-
ern blot data, target protein band intensities were nor-
malized to that of the corresponding internal control
and expressed as the fold change from baseline.
Statistical analysis was performed by one-way
ANOVA followed by Bonferroni’s post hoc test or
unpaired t-test. All statistical analyses were performed
using IBM SPSS, v. 23 (Chicago, IL, USA), and the
statistical signiﬁcance was set at p< 0.05.
Results
Effects of TRPM8 stimulation on the heat pain
threshold in a mouse meningeal inflammation
model
Under inﬂammatory conditions, TRPV1 activity at
nociceptors is enhanced, causing thermal hyperalge-
sia/allodynia (24). Such TRPV1 hyperactivity can be
assessed by a reduction in the heat pain threshold
(24,25). After IS was administered to the dura in vehi-
cle-treated wild-type mice, the heat pain threshold was
signiﬁcantly lower at six hours than at baseline
(42.4 1.5C vs. 43.6 1.0C at baseline, p< 0.001,
ANOVA, N¼ 30 at each time point, Figure 1(a) and
Table 1). The threshold temperature further decreased,
reaching a peak (lowest threshold temperature) on Day
2 post-treatment (41.0 1.9C, p< 0.001 vs. baseline,
ANOVA, N¼ 30 at each time point, Figure 1(a) and
Table 1). The heat pain threshold returned to the pre-
treatment level by Day 6 (43.5 0.8C, N¼ 30,
Figure 1(a) and Table 1). Icilin is an established
TRPM8 agonist (3,26). Compared to vehicle-treated
mice, icilin-treated mice exhibited signiﬁcantly
higher threshold temperatures at Day 1 and Day 2
(43.3 0.8C vs. 41.8 1.6C at Day 1, 43.2 0.6C
vs. 41.0 1.9C at Day 2, p< 0.001, ANOVA, N¼ 30
each, Figure 1(a) and Table 1). In sham-operated wild-
type mice, icilin pretreatment did not have any eﬀect
on the heat threshold temperature (Figure 1(b) and
Tabl 1). The inhibitory eﬀect of icilin was not observed
in TRPM8 KO mice (Figure 1(c) and Table 1). The
sham operation did not alter the threshold temperature
throughout the examination period in either vehicle-
treated or icilin-treated TRPM8 KO mice (Figure 1(d)
and Table 1). Our two-way ANOVA revealed that
there was no signiﬁcant eﬀect of mouse genotype on
the development of meningeal inﬂammation-induced
heat pain threshold changes (F value¼ 1.414,
p¼ 0.235).
TRPM8 and TRPV1 expression changes in TG
neurons after IS-induced meningeal inflammation
Next, we sought to determine the changes in the
TRPM8 and TRPV1 expression levels in TG neurons
after IS-induced meningeal inﬂammation by immuno-
histochemistry and in situ hybridization. In control and
sham-operated mice, immunostaining of TG sections
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Figure 1. Temporal profiles of the heat pain threshold temperatures after the induction of IS-induced meningeal inflammation.
(a) IS-induced meningeal inflammation lowered the heat pain threshold temperature at six hours and Days 1 and 2 in vehicle
(DMSO)-treated wild-type mice (filled triangle, N¼ 30 from six independent experiments). In contrast, there was no change in
threshold temperature when compared to that of pre-IS Baseline in icilin-pretreated WT mice (filled circle, N¼ 30 from six
independent experiments). *p< 0.001, ANOVA, Bonferroni’s post hoc test, compared to baseline. $p< 0.001, ANOVA, Bonferroni’s
post hoc test, between-group difference at the same time point. (b) In sham-operated wild-type mice, there were no temporal changes
in the heat pain threshold temperature. Icilin did not affect the heat pain threshold temperature. (N¼ 30 from six independent
experiments in each group). (c) In TRPM8 KO mice, there were no antinociceptive effects of icilin on IS-induced threshold tem-
perature changes (N¼ 30 from six independent experiments in each group). (d) In sham-operated TRPM8 KO mice, the heat pain
threshold temperature did not change throughout the experimental period. There was no significant effect of icilin on the heat pain
threshold temperature. (N¼ 30 from six independent experiments in each group).
Table 1. Quantitative data of thermal pain threshold changes.
Genotype Manipulation Treatment Baseline 6 hours Day 1 Day 2 Day 6
Wild-type IS DMSO 43.6 1.0 42.4 1.5* 41.8 1.6*,$ 41.0 1.9*,$ 43.5 0.8
Icilin 43.5 0.8 43.2 0.9 43.3 0.8 43.2 0.6 43.7 0.8
Sham DMSO 43.6 0.5 43.5 0.4 43.5 0.5 43.9 0.5 43.7 0.6
Icilin 43.4 0.4 43.6 0.5 43.4 0.4 43.5 0.4 43.7 0.6
TRPM8 KO IS DMSO 43.7 0.4 41.8 1.0* 41.3 0.7* 40.3 1.1* 43.2 0.6
Icilin 43.1 0.8 41.3 1.1* 41.0 1.2* 39.8 1.5* 42.7 0.9
Sham DMSO 43.7 0.7 43.4 0.8 43.4 0.9 43.3 0.6 43.6 0.8
Icilin 43.4 0.6 43.1 0.6 43.1 0.6 43.3 0.5 43.3 0.6
mean SD (C).
*p< 0.001, vs. Baseline, ANOVA, Bonferoni’s post-hoc test.
$p< 0.001, vs. icilin-treated, ANOVA, Bonferoni’s post-hoc test.
Kayama et al. 5
revealed that TRPV1 and TRPM8 proteins were
expressed in small- to medium-sized TG neurons, and
only a small number of cells were double-positive for
both TRPs (Figure 2(a), left column, arrowheads).
After the induction of meningeal inﬂammation, how-
ever, the numbers of TG neurons expressed in either or
both TRPs increased over the next two days before
returning to baseline by Day 6 (Figure 2(a) and (b)).
We carried out immunostaining for TG tissue sections
obtained from TRPM8 KO mice with the same
TRPM8 antibody. There was no signiﬁcant immunor-
eactivity in these samples (Figure 2(c)). In situ hybrid-
ization indicated that IS-induced meningeal
inﬂammation upregulated TRPM8 transcriptional
activity (Figure 2(d)).
Labeling of TG neurons after retrograde tracer
administration at the dura and face
The increased colocalization of both TRPs in TG neu-
rons during meningeal inﬂammation suggests that these
receptor channels interact to modulate TG neuron
activity and sensory pain thresholds. To address
whether interventions at diﬀerent trigeminal innerv-
ation sites can interact within the same TG neuron,
we performed a dual axonal tracer labeling study by
applying FG and DiI to the dura and face, respectively
(Figure 3(a)). Because dural aﬀerents are known to pro-
ject to the V1 and V2 divisions of the TG (27,28), and
the receptive ﬁelds subjected to thermal stimulation
corresponded to the V1 and V2 areas in our behavioral
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Figure 2. Changes in TRPM8 and TRPV1 expression in TG neurons during IS-induced meningeal inflammation. (a) Photomicrographs
showing TRPM8-positive and TRPV1-positive TG neurons. TG neurons double positive for TRPM8 and TRPV1 are indicated by
arrowheads. Bar¼ 15 mm. (b) Left: The ratios of TRPM8-positive (white) and TRPV1-positive (black) neurons to total neurons are
shown in the bar graph. **p< 0.001, compared to control, ANOVA, Bonferroni post hoc test. Right: The colocalization ratio of TRPM8
and TRPV1 in TG neurons is shown in the bar graph. **p< 0.001, compared to control, ANOVA, Bonferroni post hoc test. (c) There
was no significant immunoreactivity in TRPM8 KO mouse TG tissue with the same TRPM8 antibody. Bar¼ 20mm. (d) TG neurons
positive for TRPM8 transcripts visualized by in situ hybridization. For simplicity, only data for Sham (sham-operated animals) and Day 2
and Day 6 post-IS are displayed. Bar¼ 30 mm.
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test, we conducted quantitative analyses on TG neu-
rons in the V1 and V2 divisions. The proportion of
FG-labeled TG neurons receiving dural aﬀerents was
higher in the V1 division than in the V2 division (14.3%
vs. 7.7%, p< 0.001, chi-square test, Figure 3(b)). The
proportion of TRPV1-positive neurons was higher in
the V2 division than in the V1 division (15.5% vs.
12.1%, p< 0.001, chi-square test, Figure 3(b)). The pro-
portion of TG neurons dually innervating the dura and
face in all of the face-innervating TG neurons was
higher in the V1 division (47.4% vs. 23.5%, p< 0.001,
chi-square test, Figure 3(b)). The proportions of TG
neurons dually innervating the dura and face in all
the face-innervating TG neurons were equivalent
between the two divisions (52.8% and 52.7% in V1
and V1, respectively, p¼ 0.519, chi-square test,
Figure 3(b)). Approximately half of these dually inner-
vating TG neurons were TRPV1-positive (41.0% and
52.3% in V1 and V2, respectively, p¼ 0.024, chi-square
test, Figure 3(b)).
Functional interactions between TRPM8
and TPPV1 in cultured cells
In light of the histological results showing elevated
TRPM8/TRPV1 coexpression during TG inﬂammation
(and thermal allodynia), we explored whether TRPM8
activity antagonized TRPV1-mediated functions within
identical cells. We ﬁrst made an expression construct
for an EmGFP-rat full-length TRPM8-V5 fusion pro-
tein (Figure 4(a)) to transfect PC12 cells. EmGFP-
positive PC12 cells exhibited a steeper icilin-induced
intracellular calcium rise at higher EmGFP (TRPM8)
expression levels, validating the functionality of our
expression construct (Figure 4(b)). Subsequently, we
prepared PC12 cells stably expressing the rat full-
length TRPV1 protein. We previously demonstrated
that the TRPV1 agonist capsaicin increases JNK phos-
phorylation via TRPV1 in a dose-dependent manner
(22). Hence, we used JNK phosphorylation as a surro-
gate marker of TRPV1 activation. These cells were then
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Figure 3. Labeling of TG neurons after retrograde tracer administration at the dura and face. (a) Identification of TG neurons
innervating the dura (FG labeling) and/or face (DiI labeling). TRPV1-expressing cells double positive for FG and DiI are indicated by an
arrowhead. ATG neuron innervating only the face is indicated by an arrow. TRPV1-negative TG neurons innervating only the dura (#)
and a TRPV1-negative TG neuron dually innervating the dura and face (*) are indicated. Bar: 10mm. (b) Quantitative data for
retrograde axonal labeling and TRPV1 immunostaining in TG neurons are presented. The data were analyzed by chi-square test.
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transfected with the EmGFP-TRPM8-V5 expression
cassette to achieve coexpression of TRPV1 and
TRPM8. We then assessed the interaction between
receptor molecules by measuring JNK phosphorylation
as a surrogate index of TRPV1 activity (Figure 4(c),
upper row). Concomitant treatment with icilin signiﬁ-
cantly suppressed capsaicin-induced JNK phosphor-
ylation in the presence of TRPM8 expression
(Figure 4(c)).
Discussion
Stimulation of TRPM8 reversed the thermal allodynia
associated with IS-induced meningeal inﬂammation.
The TRPM8-mediated antinociceptive action was
dependent on the presence of meningeal inﬂammation
because TRPM8 stimulation did not elevate the heat
pain threshold temperature in sham-operated animals.
This ﬁnding suggested that meningeal inﬂammation
gave rise to a situation that enabled TRPM8 to interact
with TRPV1. Consistently, IS-induced meningeal
inﬂammation increased the proportion of TRPM8-
positive neurons in the TG by transcriptional upregula-
tion, and there was a concomitant increase in the
colocalization of TRPM8 with TRPV1. Retrograde
axonal tracer labeling disclosed the presence of dura-
innervating TG neurons that sent collaterals to the face
as well, and approximately half of these TG neurons
were TRPV1-positive. Furthermore, our cell experi-
ments showed that TRPM8 stimulation attenuated
TRPV1-induced phosphorylation of JNK, implying
that TRPM8 can antagonize TRPV1 function in a
cell-autonomous manner. Collectively, our data suggest
that facial TRPM8 activation is a promising thera-
peutic intervention for controlling TRPV1 activity of
dura-innervating TG neurons, which is likely to have
important relevance to migraine therapy.
Although the origin of migraine headache is still a
matter of controversy (29), recent success in migraine
prophylaxis with antibodies against CGRP or its recep-
tor strongly supports the role of peripheral
CGRP-positive trigeminal terminals in the dura
(8–11). CGRP is thought to induce degranulation of
mast cells in the dura, which contributes to the devel-
opment of inﬂammation (6,30). It follows that such
inﬂammation sensitizes the trigeminal system, and, con-
sequently, normally innocuous cranial vascular pulsa-
tions become perceivable as throbbing pain during
migraine attacks (7). IS-induced meningeal inﬂamma-
tion has been used as a classic animal model of
migraine (20,21). Electrophysiological studies by
Burstein et al. (20) demonstrated that TG neurons
became sensitized to mechanical and thermal stimula-
tion to the face at 20min after topical IS treatment to
the dura. Their subsequent study showed that the
electrical sensitization of TG neurons to thermal
stimulation persisted for at least two hours after IS
treatment (21). In their study, the cutaneous receptive
ﬁelds innervated by sensitized TG neurons included
the whisker pads as well as the periorbital regions
(20,21). Wieseler et al. (19) also demonstrated devel-
opment of mechanical allodynia by performing von
Frey ﬁlament testing in a similar IS-induced meningeal
inﬂammation model. Furthermore, our behavioral
data delineated the temporal proﬁle of facial thermal
allodynia, as seen by a lowered threshold temperature
for head withdrawal, in a more extended time window.
Facial thermal allodynia was most marked at Day 2,
but had resolved by Day 6 after IS-induced meningeal
inﬂammation. These experimental data indicate that
an intracranial inﬂammatory event is capable of indu-
cing extracranial altered sensory functions. In the clas-
sic view, such a phenomenon should be explained by
sensory integration at the level of the brainstem, and
development of extracranial allodynia/hyperalgesia is
interpreted as an indication of central sensitization
(31,32). However, recent evidence has raised the pos-
sibility that sensory input from intracranial and extra-
cranial locations can converge at the level of TG
neurons. Kosaras et al. (33) identiﬁed abundant
nerve ﬁbers along the sutures, some of which appeared
to emerge from the dura. Schueler et al. (34) observed
that dextran amines applied to the periosteum labeled
the dura, TG, and spinal trigeminal nucleus. In agree-
ment with this histological observation, their electro-
physiological recordings revealed aﬀerent ﬁbers with
mechanosensitive receptive ﬁelds both in the dura
and in the parietal periosteum (34). Our retrograde
axonal tracer study has provided further anatomical
evidence for sensory integration at the level of the TG
neurons. Our observation that the V1 division exhib-
ited a higher proportion of dually innervating neurons
of the entire population of dural aﬀerent neurons was
consistent with previous reports (27,28).
TRPV1 is known to be implicated in inﬂammation-
related sensitization to thermal stimulation. Genetic
deletion of TRPV1 conferred complete resistance to
carrageenan-induced thermal hyperalgesia in mice
(25). The pivotal role of TRPV1 in inﬂammation-
induced thermal hyperalgesia/allodynia has been
substantiated by other studies (35–40). Regarding the
relationship between TRPV1 and TRPM8, there are
human studies showing that TRPM8 agonists, such
as menthol (41) and peppermint oil (42), attenuate
TRPV1-mediated pain in the trigeminal territory,
although the precise mechanism underlying such anti-
nociceptive actions remains obscure. There have
been several reports on the coexistence of TRPV1
and TRPM8 in individual TG neurons (43–45). In
the present study, we found that TRPM8 expression
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was increased in TG neurons after IS-induced
meningeal inﬂammation through transcriptional upre-
gulation. As a result, the number of TRPM8/TRPV1-
positive TG neurons was increased, and the most
pronounced colocalization of both TRP channels
was observed with the greatest eﬃcacy of icilin for
relieving thermal allodynia. These ﬁndings support
the view that the analgesic action of icilin is exerted
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Headache Headache
Headache
Facial Allodynia
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Facial Allodynia
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Figure 5. Proposed mechanism by which facial TRPM8 activation alleviates meningeal inflammation-mediated thermal allodynia.
(a) In the resting state, there are few TG neurons that express both TRPV1 and TRPM8. Some of the dural afferent TG neurons send
collaterals to the face as well. (b) Meningeal inflammation can activate TRPV1-positive TG neurons, which causes headache and facial
thermal allodynia. (c) After a while, TRPM8 expression is enhanced by transcriptional upregulation. As a consequence, the number
of TRPM8/TRPV1-positive TG neurons increases. Such TRPM8 upregulation in TRPV1-positive cells also occurs in TG neurons
innervating both the dura and face. (d) In this condition, facial TRPM8 activation can alleviate TRPV1-mediated thermal allodynia
and, possibly, headache. In this paradigm, opposing actions derived from the intracranial (dura) and extracranial (facial tissue) tissue
can interact with each other in a cell-autonomous fashion.
TNC: trigeminal nucleus caudalis.
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at the level of primary sensory neurons (TG neurons)
via TRPM8.
Our statistical analysis showed that genetic abla-
tion of TRPM8 itself did not aﬀect the trajectory of
heat pain threshold alterations after IS-mediated men-
ingeal inﬂammation. However, we found a trend indi-
cating that icilin treatment led to a non-signiﬁcant but
lower heat pain threshold temperature throughout the
examination period in IS-mediated meningeal inﬂam-
mation-subjected TRPM8 KO mice (Figure 3(c)
and Table 1). This raises the possibility that icilin can
cause heat hyperalgesia/allodynia through its TRPM8-
independent action(s). TRPM8 modulators have been
reported to be able to cause altered body temperature
and paradoxical temperature sensation (46–48). These
facts should be kept in mind with attempts to use
TRPM8 modulators, including icilin, in clinical
practice.
We previously demonstrated that JNK phosphoryl-
ation can serve as a surrogate marker of TRPV1 activ-
ity in our cell system (22). In the present study, icilin
pretreatment was observed to reduce TRPV1-mediated
phosphorylation of JNK only in the presence of heter-
ologous TRPM8 expression. To the best of our know-
ledge, such a functional interaction between TRPM8
and TRPV1 in a cell-autonomous manner has been
demonstrated only in colonic sensory neurons (49).
How can facial TRPM8 activation alleviate the thermal
allodynia induced by meningeal inﬂammation in a cell
autonomous manner? In the basal condition, there are
only a small number of TRPM8/TRPV1-positive TG
neurons (Figure 5(a)). Meningeal inﬂammation acti-
vates TRPV1-positive dura aﬀerent TG neurons.
After meningeal inﬂammation, TRPM8 expression is
gradually upregulated through transcriptional activa-
tion, which leads to increased coexpression of
TRPM8 and TRPV1. Some of these TRPM8/TRPV1-
positive neurons innervate the dura and face
(Figure 5(b) and (c)). In this state, facial TRPM8 stimu-
lation can reverse TRPV1-mediated thermal allodynia
in a cell-autonomous manner (Figure 5(d)).
There are several limitations to our study. Expansion
of the receptive ﬁeld has been recognized as an import-
ant feature of IS-induced facial thermal allodynia (21).
Unfortunately, our experimental device for facial heat
pain testing was not suitable for spatial assessment of
receptive ﬁelds. Moreover, histological analysis of dural
tissue after IS-induced inﬂammation was impossible in
our experimental model because of the considerable
adhesion between the skull and dura after IS adminis-
tration. We previously reported that TRPV1-positive
nerve ﬁbers are abundant in the dura (50).
Meanwhile, there is a controversy concerning dural
innervation of TRPM8-positive ﬁbers. Local icilin
administration to the dura caused cutaneous allodynia
in rats (51), indicating that the dura was responsive to
TRPM8 stimulation. However, a previous study using
transgenic mice expressing farnesylated enhanced GFP
from one TRPM8 allele demonstrated that dural
TRPM8-positive nerve ﬁbers were scarce in adulthood
owing to postnatal ﬁber pruning (52). Our ﬁnding
implies that TRPM8 expression might be enhanced by
local inﬂammation in the meningeal nerve terminals as
well as in TG neurons. However, we were unable to
clarify this point. In addition, we did not address any
central action of TRPM8 in the present study. Our data
do not exclude the coexistence of any central mechan-
isms with respect to the antinociceptive eﬀect of facial
TRPM8 stimulation. As for cell-based experiments, we
should have ideally used primary TG neuron-rich cul-
tures. That may have rendered our study much more
relevant to the actual clinical setting. Capsaicin concen-
trations required for JNK phosphorylation in our cells
(22) and CGRP release in primary TG neurons (53)
seem to diﬀer from each other. However, in the primary
culture system, the number of obtained viable TG neu-
rons is not so high that biochemical analysis using west-
ern blotting would be almost impossible. Instead, by
using PC12 cells, which derive from the neural crest
like TG neurons, we were able to obtain biochemical
data steadily. Importantly, the TRPV1 expression level
in our PC12 cells was not so high, because we used a
stable TRPV1-expressing cell line (22).
In summary, our results strongly suggest that facial
TRPM8 activation can exert an antimigraine action by
inactivating TRPV1 function at the level of TG neu-
rons. While these ﬁndings may provide important
insights into migraine pathophysiology, it should be
noted that TRPM8 and TRPV1 are also involved in
the pathophysiology of other craniofacial disorders,
such as meningitis, so the applicability of our results
may be extensive.
Article highlights
. TRPM8 activation can exert an analgesic action by antagonizing TRPV1 at the level of TG neurons.
. Meningeal inﬂammation upregulates TRPM8 expression in TG neurons by enhancing transcriptional
activity.
. Facial TRPM8 activation is a promising therapeutic intervention for migraine.
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